JP2023548471A5 - - Google Patents

Info

Publication number
JP2023548471A5
JP2023548471A5 JP2023526126A JP2023526126A JP2023548471A5 JP 2023548471 A5 JP2023548471 A5 JP 2023548471A5 JP 2023526126 A JP2023526126 A JP 2023526126A JP 2023526126 A JP2023526126 A JP 2023526126A JP 2023548471 A5 JP2023548471 A5 JP 2023548471A5
Authority
JP
Japan
Prior art keywords
polypeptide
sequence
heavy chain
light chain
variable light
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548471A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/057452 external-priority patent/WO2022094343A1/en
Publication of JP2023548471A publication Critical patent/JP2023548471A/ja
Publication of JP2023548471A5 publication Critical patent/JP2023548471A5/ja
Pending legal-status Critical Current

Links

JP2023526126A 2020-10-30 2021-10-29 抗SARS-CoV-2抗原抗体並びに関連する組成物及び方法 Pending JP2023548471A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063108158P 2020-10-30 2020-10-30
US63/108,158 2020-10-30
US202063108791P 2020-11-02 2020-11-02
US63/108,791 2020-11-02
US202063112096P 2020-11-10 2020-11-10
US63/112,096 2020-11-10
US202163190097P 2021-05-18 2021-05-18
US63/190,097 2021-05-18
PCT/US2021/057452 WO2022094343A1 (en) 2020-10-30 2021-10-29 Anti-sars-cov-2 antigen antibodies and related compositions and methods

Publications (2)

Publication Number Publication Date
JP2023548471A JP2023548471A (ja) 2023-11-17
JP2023548471A5 true JP2023548471A5 (https=) 2024-11-05

Family

ID=81384373

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526126A Pending JP2023548471A (ja) 2020-10-30 2021-10-29 抗SARS-CoV-2抗原抗体並びに関連する組成物及び方法

Country Status (8)

Country Link
US (1) US20230382979A1 (https=)
EP (1) EP4237443A4 (https=)
JP (1) JP2023548471A (https=)
AU (1) AU2021369409A1 (https=)
BR (1) BR112023008365A2 (https=)
CA (1) CA3200263A1 (https=)
IL (1) IL302460A (https=)
WO (1) WO2022094343A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4649096A2 (en) * 2023-01-10 2025-11-19 Sana Biotechnology, Inc. Cd19-specific antibody constructs and compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11352425B2 (en) * 2016-11-08 2022-06-07 Absos, Llc Anti-CD47 antibodies
AU2018346978B2 (en) * 2017-10-13 2024-02-15 Mapp Biopharmaceutical, Inc. Anti-respiratory syncytial virus antibodies, methods of their generation and use
KR20250107297A (ko) * 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편

Similar Documents

Publication Publication Date Title
US11891444B2 (en) Variable regions for NKp46 binding proteins
JP2024050548A (ja) Cd47に対するヒト化及びキメラモノクローナル抗体
US20240392003A1 (en) Multispecific antibodies having specificity for ror1 and cd3
JP2022523507A5 (https=)
JP2023527609A5 (https=)
US20250282879A1 (en) Multispecific antibodies having specificity for il-4r and il-31
JP2022548043A5 (https=)
US11365240B2 (en) Anti-HSA antibodies
JP2021530244A5 (https=)
TW202212355A (zh) 多特異性抗體及其用途、用於產生其之方法、包括其之藥物組合物、編碼其之核酸序列、包括核酸序列的載體及包括載體的宿主細胞
JP2023536631A5 (https=)
JP2023548471A5 (https=)
JP2025506341A5 (https=)
US20230203162A1 (en) Multispecific antibody
JP2023536630A5 (https=)
JP2022541192A5 (https=)
US20250382363A1 (en) Antibody Variable Domains And Antibodies Having Decreased Immunogenicity
JP2022544068A5 (https=)
CA3143957A1 (en) Anti-pd-l1 antibodies
EP4273162A1 (en) Antibody variable domains and antibodies having decreased immunogenicity
TW202415677A (zh) 抗TNFα抗體及組合物
JP2025503176A5 (https=)
WO2023143273A1 (zh) 新型长效化和高活性且更安全的抗体构建体
US20240084039A1 (en) Antibody variable domains and antibodies having decreased immunogenicity
JP2024513700A5 (https=)